Compare CRUS & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRUS | PCVX |
|---|---|---|
| Founded | 1984 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 9.0B |
| IPO Year | 1997 | 2020 |
| Metric | CRUS | PCVX |
|---|---|---|
| Price | $173.62 | $59.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $157.00 | $88.25 |
| AVG Volume (30 Days) | 631.7K | ★ 1.1M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.45 | N/A |
| EPS | ★ 6.27 | N/A |
| Revenue | ★ $1,896,077,000.00 | N/A |
| Revenue This Year | $7.12 | N/A |
| Revenue Next Year | $0.49 | N/A |
| P/E Ratio | $27.52 | ★ N/A |
| Revenue Growth | ★ 5.99 | N/A |
| 52 Week Low | $91.32 | $28.09 |
| 52 Week High | $173.84 | $65.00 |
| Indicator | CRUS | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 76.93 | 49.66 |
| Support Level | $115.31 | $52.04 |
| Resistance Level | N/A | $64.16 |
| Average True Range (ATR) | 4.76 | 2.20 |
| MACD | 1.23 | -0.21 |
| Stochastic Oscillator | 92.88 | 17.50 |
Cirrus Logic Inc is a provider of integrated circuits for audio and voice signal processing applications. The firm's products are organized into two streams: portable audio products, and HPMS Products. These products include aAmplifiers, codecs, smart codecs, analog-to-digital converters, digital-to-analog converters and standalone digital signal processors, Camera controllers, haptics and sensing solutions, and battery and power ICs. Roughly half of the firm's revenue is generated in China, with the rest coming from the United States, Europe, South Korea, and countries across the world.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.